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Abstract 
The most common genetic cause of neonatal diabetes and hyperinsulinism are 
pathogenic variants in ABCC8 and KCNJ11. These genes encode the subunits of the 
beta-cell ATP sensitive potassium channel, a key component of the glucose-
stimulated insulin secretion pathway. Mutations in the two genes cause dysregulated 
insulin secretion; inactivating mutations cause an over-secretion of insulin leading to 
congenital hyperinsulinism, whilst activating mutations cause the opposing 
phenotype, diabetes. This review focuses on variants identified in ABCC8 and 





















ATP-sensitive potassium (KATP) channels were found to couple glucose metabolism 
to membrane electrical activity and insulin release over 30 years ago (Ashcroft, et al., 
1984; Cook and Hales, 1984; Rorsman and Trube, 1985). This landmark discovery 
was fundamental to furthering understanding of the insulin secretion pathway 
whereby glucose metabolism results in a change in ratio of ADP and ATP. Binding of 
ATP to the channel induces channel closure, depolarisation of the membrane and 
activation of voltage-dependent calcium channels leading to calcium influx and 
insulin granule exocytosis (Figure 1a).  
 
Given the role of the KATP channel in insulin secretion, it is not unexpected that 
variants in KCNJ11, encoding the four pore-forming inwardly rectifying Kir6.2 
subunits, and ABCC8, encoding the four sulphonylurea receptor 1 (SUR1) subunits 
of the channel, can cause hypo- or hyperglycaemia (Babenko, et al., 2006; Gloyn, et 
al., 2004b; Thomas, et al., 1996; Thomas, et al., 1995). Identifying these mutations is 
important for informing prognosis, medical management and recurrence risk.  
 
Over recent years, the number of variants identified in these two genes has 
expanded tremendously. In 2006, 124 disease-causing mutations were reported 
which increased to 265 pathogenic variants 3 years later (Flanagan, et al., 2009; 
Gloyn, et al., 2006b).  By combining published reports together with data from 5 
international molecular genetic screening laboratories in the UK, Denmark, France 
and the United States of America we now report 953 pathogenic ABCC8 and 
KCNJ11 variants (Supp Tables S1-S6) and discuss the role of these genes in 
congenital hyperinsulinism (CHI) and monogenic diabetes.  
 
Congenital Hyperinsulinism 
CHI is characterised by the inappropriate secretion of insulin despite low blood 
glucose which can result in irreversible brain damage if not promptly treated 
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(Helleskov, et al., 2017). The condition has a variable phenotype usually presenting 
during the neonatal period or infancy with seizures and/or coma and a large birth 
weight due to high levels of insulin acting as a growth factor in utero. 
 
Although most cases of CHI are sporadic rare familial forms have been well 
documented. Sporadic CHI has an estimated incidence of between 1 in 27,000 and 1 
in 50,000 live births (Glaser, et al., 2000; Otonkoski, et al., 1999). However, in some 
isolated populations, or in countries with high rates of consanguineous unions, the 
incidence is higher (i.e. 1 in 2,675 to 1 in 3,200) (Mathew, et al., 1988; Otonkoski, et 
al., 1999).  
 
CHI due to KATP channel mutations  
Loss-of-function ABCC8 mutations were first described in 1995 (Thomas, et al., 
1995). These mutations either prevent trafficking of the channel to the membrane 
surface or are associated with channels that reach the surface but are not fully 
responsive to MgADP activation (figure 1) (Ashcroft, 2005; Nichols, et al., 1996; 
Taschenberger, et al., 2002). The majority of ABCC8 loss-of-function mutations are 
recessively acting with a small number of dominant missense mutations reported 
which produce channels that traffic to the membrane but have impaired mgADP 
activation.  
 
Fewer loss of function mutations have been reported in KCNJ11  in keeping with the 
gene being much smaller (1173 vs 4749 bases, respectively) (Thomas, et al., 1996). 
Similarly to ABCC8, both dominant and recessively acting KCNJ11 mutations have 
been described (Pinney, et al., 2013). Together mutations in these two genes 
account for 36%-70% of CHI cases (Kapoor, et al., 2013; Snider, et al., 2013). 
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Mouse models for KATP channel CHI exist, however, their inability to fully recapitulate 
the human phenotype means that they have limited value for studying specific 
disease mechanisms. For example, mice generated with a deletion of ABCC8 or 
KCNJ11, or the homozygous recessive KCNJ11 mutation p.(Tyr12Ter), do not have 
the sustained neonatal hypoglycaemia observed in humans with homozygous null 
mutations. Instead the blood glucose levels normalise in the mouse within a few days 
of birth with glucose intolerance developing in later life (Hugill, et al., 2010; Miki, et 
al., 1998; Seghers, et al., 2000). The differences in the phenotype between mice and 
humans are not fully understood but highlight the need to develop human-specific 
models for studying disease mechanisms.  
 
Clinical Management of KATP Channel CHI 
In 2015, the Pediatric Endocrine Society published recommendations for the 
evaluation and management of persistent hypoglycaemia in neonates, infants and 
children (Thornton, et al., 2015). The main treatment for CHI is the KATP channel-
opener diazoxide, however patients with ABCC8/KCNJ11 mutations which prevent 
trafficking to the membrane do not respond to the drug as diazoxide targets the 
SUR1 subunit of the KATP channel. For approximately 50% of patients with mutations 
that do not prevent the channel from reaching the membrane, diazoxide is an 
effective treatment (Boodhansingh, et al., 2019). For patients with diazoxide-
unresponsive CHI, second line treatment with somatostatin analogues may be helpful 
to control hypoglycaemia although adverse effects to somatostatin analogues, and 
likewise diazoxide, have been reported (Demirbilek, et al., 2014; Herrera, et al., 
2018). 
 
The mode of inheritance of the KATP channel mutation determines the pancreatic 
histological subtype (de Lonlay, et al., 1997; de Lonlay, et al., 2002; Jack, et al., 
2000; Rahier, et al., 1984). Inheritance of two recessively–acting or one dominant 
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ABCC8/KCNJ11 mutation results in diffuse disease affecting the entire pancreas. 
Focal disease is caused by somatic loss of the maternal chromosome 11p15.5 region 
by uniparental disomy which unmasks a paternally-inherited KATP channel mutation at 
11p15.1. These focal lesions often appear histologically as small regions of islet 
adenomatosis which develop as a result of the imbalanced expression of maternally 
imprinted tumour suppressor genes H19 and p57Kip2, and the increased expression of 
the paternally derived insulin-like growth factor II gene (Craigie, et al., 2018; Damaj, 
et al., 2008; de Lonlay, et al., 1997). Rarely, giant focal lesions have been described 
where virtually the whole of the pancreas is affected (Ismail, et al., 2012). Atypical 
mosaic disease has also been reported in a small number of cases (Han, et al., 
2017; Houghton, et al., 2019; Hussain, et al., 2008; Sempoux, et al., 2011).  
 
The identification of a single recessively-acting KATP channel mutation in an individual 
with CHI predicts focal disease with 84-97% sensitivity with a positive predictive 
value up to 94% (Mohnike, et al., 2014; Snider, et al., 2013). 18F-DOPA PET/CT 
scanning can identify and localize a focal lesion prior to surgery (Otonkoski, et al., 
2006). Intraoperative ultrasound may further aid the surgeon to perform tissue-




Diabetes is the opposing disorder to CHI and results from hyper- rather than 
hypoglycaemia. Current estimates suggest that approximately 0.4% of all diabetes 
(and up to 3.5% of those diagnosed under 30 years of age) has a monogenic cause 
(Shepherd, et al., 2016; Shields, et al., 2017). Individuals diagnosed with monogenic 
diabetes outside of infancy are generally classified as having Maturity Onset 
Diabetes of the Young (MODY), whilst Neonatal Diabetes (NDM) describes 
congenital diabetes. In individuals with NDM, impaired insulin secretion results in a 
7 
low birth weight and hyperglycaemia diagnosed before the age of 6 months 
(Hattersley and Ashcroft, 2005). The minimal incidence of NDM has been calculated 
to be between 1 in 89,000 and 1 in 160,949 live births (Grulich-Henn, et al., 2010; 
Wiedemann, et al., 2010).  
 
Later-onset diabetes due to KATP channel mutations 
Dominantly acting mutations in the KATP channel genes have been rarely described in 
individuals with later-onset diabetes in the absence of documented hyper- or 
hypoglycaemia in the neonatal period (Tarasov, et al., 2008)(Bowman, et al., 2012; 
Hartemann-Heurtier, et al., 2009; Huopio, et al., 2003; Koufakis, et al., 2019). The 
mechanism(s) leading to this variable penetrance are not fully understood and may 
differ according to whether the mutation is causing a gain or loss of channel function. 
Interestingly, in one study the generation of a mouse model harbouring a 
homozygous dominantly-acting loss-of-function ABCC8 mutation p.(Glu1507Lys) 
recapitulated the biphasic phenotype with the mice having increased insulin secretion 
in early life and reduced insulin secretion later on. This was shown to be resulting 
from a reduction in insulin content rather than a reduction of islet number and/or size. 
Heterozygosity for the mutation did however not result in a phenotype in the mouse, 
further highlighting differences between the mouse models and human disease 
(Shimomura, et al., 2013).  
 
Neonatal diabetes due to KATP channel mutations 
Strong support for the role of gain-of-function KATP channel mutations in the aetiology 
of diabetes came from the observation that mice over-expressing a mutant KATP 
channel with reduced ATP sensitivity developed diabetes within 2 days (Koster, et 
al., 2000). In 2004, the first heterozygous activating KCNJ11 mutations causing NDM 
were described in humans with activating ABCC8 mutations reported two years later 
(Babenko, et al., 2006; Gloyn, et al., 2004b; Proks, et al., 2006). Together mutations 
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in these two genes have now been shown to account for approximately 40% of NDM 
cases (De Franco, et al., 2015; Stoy, et al., 2008). 
 
Both dominant and recessive activating mutations are frequently identified in ABCC8. 
Conversely for KCNJ11, all but one of the mutations reported so far, p.(Gly324Arg), 
have been dominantly acting. The majority (~60%) of dominant mutations arise “de 
novo” so there is often no family history of diabetes although germline mosaicism has 
been observed in some families (Edghill, et al., 2007; Gloyn, et al., 2004a). 
 
There is added complexity associated with ABCC8 mutations, as compound 
heterozygosity for both an activating and an inactivating mutation can cause diabetes 
(Ellard, et al., 2007). Furthermore, a recessively-inherited ABCC8 nonsense variant 
has been reported in two cases with NDM which leads to the deletion of the in-frame 
exon 17 likely resulting in enhanced sensitivity of the channel to intracellular 
MgADP/ATP (Flanagan, et al., 2017).  
 
The specific KATP channel mutation identified determines whether the diabetes will 
cause permanent or transient NDM (Gloyn, et al., 2005; Patch, et al., 2007). Variable 
penetrance within families with mutations leading to transient diabetes is observed 
with some individuals being diagnosed with diabetes at birth yet others developing 
diabetes for the first time in adulthood (see previous section on adult-onset diabetes) 
(Flanagan, et al., 2006). 
 
Spectrum of central nervous system (CNS) features in KATP channel NDM  
CNS features are frequently reported in individuals with KATP channel NDM due to the 
Kir6.2 and SUR1 proteins being expressed in the brain (Karschin, et al., 1997; Liss, 
et al., 1999; Sakura, et al., 1995; Schmahmann and Sherman, 1998). The most 
severe neurological phenotype is termed Developmental delay, Epilepsy and 
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Neonatal Diabetes (DEND) syndrome which includes muscle weakness and 
hypotonia (Hattersley and Ashcroft, 2005). Intermediate DEND (iDEND) syndrome is 
diagnosed when epilepsy is absent or presents after the age of 12 months (Gloyn, et 
al., 2006a). Clinical studies have reported CNS features in ≈20-30% of individuals 
with KATP channel permanent NDM (De Franco, et al., 2015; Massa, et al., 2005; 
Sagen, et al., 2004).  
 
Since these initial reports, studies in larger cohorts of individuals affected with KATP 
channel NDM have characterised the neurological features in more detail. Additional 
features reported include autism and attention deficit hyperactivity disorder (ADHD), 
anxiety and sleep disorders, dyspraxia and learning difficulties resulting in impaired 
attention, memory, visuospatial abilities and executive function (Beltrand, et al., 2015; 
Bowman, et al., 2016; Bowman, et al., 2018a; Bowman, et al., 2017; Busiah, et al., 
2013; Landmeier, et al., 2017). Importantly, it is now recognised that some degree of 
impairment can be detected on neuropsychological testing in the majority of patients 
with KATP channel mutations even if there is no obvious CNS involvement (Busiah, et 
al., 2013; Carmody, et al., 2016). 
 
Clinical management of neonatal diabetes and CNS features due to KATP 
channel mutations 
The identification of a KATP channel mutation can impact on the medical management 
of patients with NDM as ~90% can transfer from insulin injections to high-dose 
sulphonylurea tablets (Pearson, et al., 2006; Zung, et al., 2004). Sulphonylureas bind 
to the SUR1 subunit of the KATP channel and close it independently of ATP, resulting 
in excellent long-term glycaemic control and improved quality of life for affected 
patients and their families (Babenko, et al., 2006; Bowman, et al., 2018b; Rafiq, et 
al., 2008). Patients who are unable to transfer to sulphonylureas tend to have a 
longer duration of diabetes prior to attempting transfer or functionally severe 
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mutations (Babiker, et al., 2016; Thurber, et al., 2015).  Few side effects and no 
episodes of severe hypoglycaemia involving seizures or loss of consciousness have 
been reported in individuals with sulphonylurea-treated neonatal diabetes (Bowman, 
et al., 2018b; Codner, et al., 2005; Kumaraguru, et al., 2009; Lanning, et al., 2018). 
 
Sulphonylureas can improve the neurological features in people with KATP channel 
NDM, particularly in the first year of treatment (Beltrand, et al., 2015; Fendler, et al., 
2013; Stoy, et al., 2008). However, these features do not fully resolve on 
sulphonylureas and persist long-term into adulthood (Bowman, et al., 2018a; 
Bowman, et al., 2018b). Higher doses of sulphonylureas are recommended for 
patients with severe neurological features in an attempt to mitigate this 
(https://www.diabetesgenes.org/). In addition, starting sulphonylurea therapy as early 
as possible after a genetic diagnosis is crucial as the largest improvements appear to 
occur in younger patients (Beltrand, et al., 2015; Shah, et al., 2012). 
 
GENETIC VARIATION IN ABCC8 AND KCNJ11 
KCNJ11 (MIM# 600937) is located 4.5Kb from ABCC8 on chromosome 11p15.1 and 
has a single exon encoding for the 390-amino acid Kir6.2 protein (GenBank 
NM_000525.3). ABCC8 consists of 39 exons which encode for the 1,582 amino acids 
of SUR1 (NM_001287174.1) (MIM# 600509). This gene has an alternatively spliced 
recognition site at the 5’ end of exon 17 which results in two different transcripts 
differing in length by a single amino acid (GenBank AH003589.2). This alternative 
splicing has led to discrepancies in the literature for nomenclature of variants present 
in 17-39 which differ by a single amino acid depending on the isoform used (1581 
amino acids, NM_000249.3 and 1582 amino acids, NM_001287174.1). For the 
purpose of this review we have described ABCC8 variants according to the longer 




A total of 748 ABCC8 and 205 KCNJ11 pathogenic or likely pathogenic variants have 
been identified in individuals with CHI or NDM (Table 1 and Supp Tables S1 and S4 - 
please note that these tables are meant to direct to the appropriate references and 
laboratories. The tables do not provide in-depth clinical information and variants 
which had been previously reported as pathogenic with a GnomAD frequency 
compatible with the disease frequency (as calculated by 
http://cardiodb.org/allelefrequencyapp/ using a biallelic mode of inheritance, a 
prevalence of 1/50,000, an allelic heterogeneity of 0.1, genetic heterogeneity of 0.5, 
and penetrance of 0.5) were not re-assessed).  
 
Founder mutations have been identified in many populations with the best 
recognised example being the ABCC8 p.(Phe1388del) and c.3992-9G>A mutations 
present in >90% of cases from the Ashkenazi Jewish population (Nestorowicz, et al., 
1996; Otonkoski, et al., 1999). In the Irish population, a deep intronic ABCC8 founder 
mutation at position c.1333-1013G>A has been described which generates a cryptic 
splice site and causes pseudoexon activation (Flanagan, et al., 2013). Founder 
mutations have also been reported in Hispanic (Aguilar-Bryan and Bryan, 1999), 
Bedouin (Tornovsky, et al., 2004), Spanish (Fernandez-Marmiesse, et al., 2006) 
Finnish (Otonkoski, et al., 1999) and Turkish populations (Flanagan, et al., 2013). 
 
Common variation in ABCC8 and KCNJ11  
368 benign/likely benign variants and variants of uncertain significance have been 
observed in both genes (Supp Tables S2, S3, S5 and S6). Two common variants in 
linkage disequilibrium, p.(Glu23Lys) in KCNJ11 and p.(Ser1370Ala) in ABCC8,  
predispose to type 2 diabetes (Florez, et al., 2004). Whilst their effect size is small 
(odds ratio ~1.2), given that 58% of the population carry at least one lysine allele at 
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residue 23 in KCNJ11, this equates to a sizeable population risk (Gloyn, et al., 2003; 
Nielsen, et al., 2003). 
 
Variant Interpretation 
Given the highly polymorphic nature of ABCC8 and KCNJ11, the occurrence of both 
activating and inactivating mutations, the multiple modes of inheritance of disease 
and the variable penetrance associated with dominantly acting mutations, interpreting 
variants identified in these genes can be extremely challenging. Whilst the 
identification of a null ABCC8 or KCNJ11 variant(s) in an individual with CHI provides 
strong evidence for pathogenicity, finding a missense variant is insufficient to assign 
disease causality and as such additional support is required to achieve a ‘pathogenic’ 
classification according to the guidelines set out by the American College of Medical 
Genetics (Richards, et al., 2015).  
 
Large variant databases such as GnomAD and LOVD are powerful tools which aid in 
variant interpretation and allow for re-classification of variants (Fokkema, et al., 2011; 
Lek, et al., 2016). As such, some variants previously reported as pathogenic in the 
literature have now been found to be too common to be causative of disease and 
have now be reassigned as a variant of uncertain significance or a benign variant 
(Supp tables S2, S3, S5 and S6).  
 
FUTURE PROSPECTS 
Whilst sulphonylureas provide a safe and effective treatment for the majority of 
individuals with KATP channel NDM, for patients with CHI pharmacological 
management of the condition is not always successful. Current efforts are therefore 
focussing on the development of new pharmacological treatments for this condition 
(Banerjee, et al., 2017; De Leon, et al., 2008; Ng, et al., 2018; Patel, et al., 2018; 
Powell, et al., 2011; Senniappan, et al., 2014). 
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Progress is also being made in terms of genetic screening, with a recent report 
describing the use of non-invasive prenatal testing of a paternally-inherited KCNJ11 
activating mutation in cell-free fetal DNA (De Franco, et al., 2017). Implementation of 
non-invasive prenatal testing for maternally-inherited mutations will be extremely 
important as a previous study suggested that sulphonylurea can cross the placenta 
and influence fetal growth with implications for treatment of monogenic diabetes 
pregnancies (Myngheer, et al., 2014; Shepherd, et al., 2017).  
 
SUMMARY 
The discovery of both inactivating and activating KATP channel mutations has firmly 
established the critical role of the channel in insulin secretion. The highly polymorphic 
nature of the two genes along with the occurrence of both gain-of-function and loss-
of-function mutations as well as multiple different modes of inheritance can make 
variant interpretation extremely challenging. Rapid testing is absolutely crucial for all 
patients with CHI or NDM because finding a mutation has a huge impact on the 
clinical management of these conditions.  
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Figure 1: Schematic representation of insulin secretion in the pancreatic beta-
cell a) In a normal cell in a high plasma glucose environment b) In a cell with an 
activating KATP channel mutation c) In a cell with an inactivating mutation 
resulting in absence/reduction in protein at the membrane surface d) In a cell 
with a inactivating mutation that impairs the stimulatory effect of MgADP A) 
Glucose is metabolised following entry into the beta-cell via a GLUT transporter. This 
results in change in the ATP:ADP ratio leading to channel closure and membrane 
depolarisation and activation of voltage-dependent calcium channels. Calcium enters 
the cell which triggers insulin release. B) An activating mutation in a KATP channel 
gene results in the membrane being maintained in a hyperpolarised state. Calcium 
channels remain closed and insulin is not secreted. C) Loss of function mutations can 
result in an absence/reduction in protein at the membrane surface. This keeps the 
membrane in a depolarised state regardless of the metabolic state ultimately leading 
to unregulated insulin secretion D) Loss of function missense mutations can produce 
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